New Cases
- In 2020, there are expected to be 85,720 new cases of lymphoma diagnosed in the US (8,480 cases of HL, 77,240 cases of NHL
Prevalence
- There are an estimated 791,550 people living with, or in remission from, lymphoma in the US.
- There are 146,789 people living with or in remission from Hodgkin lymphoma
- There are 644,761 people living with or in remission from non-Hodgkin lymphoma
With the release of the 1975-2016 Cancer Statistics Review, the calculation of limited-duration prevalence estimates were modified to use data from the SEER 13 areas (not including the Alaska Natives Registry) using cases diagnosed from 1992 through 2015. Prior publications used data from the SEER 9 registries using cases diagnosed from 1975+. SEER 13 provides a larger population base and one which is more representative of the entire US, which allows better projections of US counts. Due to this methodology change, the estimates may differ significantly from those published in previous years.
Survival
- The 5-year relative survival rate for people with HL has more than doubled, from 40 percent in whites from 1960 to 1963 (the only data available) to 88.5 percent for all races from 2009 to 2015. The 5-year relative survival rate is 94.4 percent for all people with HL who were younger than 45 years at diagnosis.
- HL is now considered to be one of the most curable forms of cancer.
- The 5-year relative survival rate for people with NHL has risen from 31 percent in whites from 1960 to 1963 (the only data available) to 74.7 percent for all races from 2009 to 2015.
Deaths
- In 2020, an estimated 20,910 members of the US population are expected to die from lymphoma (19,940 NHL and 970 HL).